Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr122.00 SEK
Change Today -5.00 / -3.94%
Volume 191.0K
As of 12:30 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

orexo ab (ORX) Snapshot

Open
kr125.50
Previous Close
kr127.00
Day High
kr125.50
Day Low
kr118.25
52 Week High
01/29/15 - kr149.25
52 Week Low
05/22/14 - kr90.75
Market Cap
4.2B
Average Volume 10 Days
99.1K
EPS TTM
kr-1.81
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXO AB (ORX)

Related News

No related news articles were found.

orexo ab (ORX) Related Businessweek News

No Related Businessweek News Found

orexo ab (ORX) Details

Orexo AB (publ)., a specialty pharmaceutical company, engages in the development and commercialization of drugs based on patented drug delivery technologies primarily in Sweden and the United States. The company’s product portfolio comprises products on the market, proprietary development programs, and collaboration projects. Its products on the market include Zubsolv sublingual tablets for maintenance treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; Edluar, an active substance zolpidem and for the treatment of short-term insomnia; Diabact UBT, which is used to diagnose the presence of Helicobacter pylori, a bacterium that causes gastric ulcers; and Heliprobe System, which is a doctor’s office test to detect the presence of the gastric ulcer bacterium, Helicobacter pylori. The company’s development programs comprise OX51, a sublingual formulation containing alfentanil, which has completed phase II study for the prevention of acute intense pain associated with care-related diagnostic or therapeutic procedures. Its collaboration projects consist of OX-MPI for the treatment of pain and inflammation through collaboration with Boehringer Ingelheim; OX-NLA for the treatment of allergic and non-allergic rhinitis through a partnership with Meda AB; and OX-CLI for the respiratory tract diseases through collaboration with AstraZeneca. Orexo AB (publ). was founded in 1995 and is headquartered in Uppsala, Sweden.

108 Employees
Last Reported Date: 03/25/15
Founded in 1995

orexo ab (ORX) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.1M
Compensation as of Fiscal Year 2014.

orexo ab (ORX) Key Developments

Orexo AB Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2014

Orexo AB announced audited consolidated and parent earnings results for the year ended December 31, 2014. For the year, on consolidated basis, the company reported net revenues of SEK 570,316,000 compared to SEK 429,355,000 a year ago. Operating loss was SEK 25,007,000 compared to SEK 139,689,000 a year ago. Loss after financial items was SEK 52,554,000 compared to SEK 153,401,000 a year ago. Loss for the year attributable to parent company shareholders was SEK 56,584,000 compared to SEK 154,936,000 a year ago. Loss per share during the year attributable to parent company shareholders - before and after dilution was SEK 1.73 compared to SEK 5.16 a year ago. Cash outflow from operating activities was SEK 487,300,000 compared to SEK 263,201,000 a year ago. Acquisition of tangible and intangible fixed assets was SEK 71,723,000 compared to SEK 107,505,000 a year ago. Net debt was SEK 211.8 million compared to SEK 135.4 million a year ago. Loss on shareholders' equity was 27.5% compared to 88.3% a year ago. For the year, on parent basis, the company reported net revenues of SEK 398,447,000 compared to SEK 452,321,000 a year ago. Operating loss was SEK 39,522,000 compared to SEK 27,839,000 a year ago. Loss after financial items was SEK 65,417,000 compared to SEK 44,278,000 a year ago. Net loss for the year was SEK 65,951,000 compared to SEK 45,724,000 a year ago. Cash outflow from operating activities was SEK 471,954,000 compared to SEK 283,787,000 a year ago. Acquisition of tangible and intangible fixed assets was SEK 71,280,000 compared to SEK 105,941,000 a year ago.

Orexo AB to Report Fiscal Year 2014 Final Results on Mar 25, 2015

Orexo AB announced that they will report fiscal year 2014 final results on Mar 25, 2015

Orexo AB Presents at Carnegie Nordic Healthcare Seminar 2015, Mar-12-2015 08:55 AM

Orexo AB Presents at Carnegie Nordic Healthcare Seminar 2015, Mar-12-2015 08:55 AM. Venue: Regeringsgatan 56, Stockholm, Sweden.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORX:SS kr122.00 SEK -5.00

ORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ORX.
View Industry Companies
 

Industry Analysis

ORX

Industry Average

Valuation ORX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXO AB, please visit www.orexo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.